公开(公告)号：US20080113455A1

公开(公告)日：2008-05-15

申请号：US11823565

申请日：2007-06-28

申请人： Rajesh Jain ,  Tahir Malik ,  Vladimir Makarov

发明人： Rajesh Jain ,  Tahir Malik ,  Vladimir Makarov

IPC分类号： H01L21/306 ,  G05D9/00 ,  H01L21/02

CPC分类号： H01L21/32136 ,  H01J37/3056 ,  H01J2237/3174 ,  H01L21/31116

摘要： A method of planar etching of dissimilar materials with a Focused Ion Beam (FIB) system such as the OptiFIB manufactured by Credence Systems. The method includes adjusting the selectivity between the two materials, which varies when the ratio of the assisting chemistry pressure to the ion dose rate changes. This method can be used in such applications as FIB circuit edit, failure analysis, and cross sectioning.

摘要翻译： 用聚焦离子束（FIB）系统（如Credence Systems制造的OptiFIB）对不同材料进行平面蚀刻的方法。 该方法包括调节两种材料之间的选择性，当辅助化学物质压力与离子剂量率的比率发生变化时，这种选择性会发生变化。 该方法可用于FIB电路编辑，故障分析和横截面等应用。

公开(公告)号：US09642808B2

公开(公告)日：2017-05-09

申请号：US12672180

申请日：2008-08-11

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

IPC分类号： A61K31/343 ,  A61K9/20 ,  A61K9/28 ,  A61K31/365

CPC分类号： A61K9/2077 ,  A61K9/2013 ,  A61K9/2846 ,  A61K31/365

摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

公开(公告)号：US20130302383A1

公开(公告)日：2013-11-14

申请号：US13979997

申请日：2012-01-17

申请人： Rajesh Jain ,  Sarabjit Singh ,  Paramjit Singh ,  Pirthi Pal Singh

发明人： Rajesh Jain ,  Sarabjit Singh ,  Paramjit Singh ,  Pirthi Pal Singh

IPC分类号： A61K9/00 ,  A61K33/24

CPC分类号： A61K9/0053 ,  A61K9/0095 ,  A61K33/24 ,  A61K47/02 ,  A61K47/14 ,  A61K47/26 ,  A61K47/38

摘要： The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.

摘要翻译： 本发明涉及镧的液体口服药物组合物及其药学上可接受的盐。 本发明还涉及镧及其盐的液体口服药物组合物的制备，并且还提供了这些组合物在患者中治疗高磷血症的用途。

公开(公告)号：US08551451B2

公开(公告)日：2013-10-08

申请号：US13125708

申请日：2009-10-23

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Lavit Jambu

IPC分类号： A61K49/00 ,  A61K39/00 ,  A61K39/02

CPC分类号： A61K39/05 ,  A61K39/0018 ,  A61K39/08 ,  A61K39/099 ,  A61K39/102 ,  A61K39/12 ,  A61K39/13 ,  A61K39/292 ,  A61K2039/5252 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134 ,  C12N2770/32634 ,  Y02A50/466

摘要： The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.

摘要翻译： 本发明涉及包含抗原混合物的组合疫苗，用于防止诸如白喉，破伤风，无细胞百日咳和由流感嗜血杆菌和脊髓灰质炎病毒引起的感染。 本发明还涉及包含用于防止引起的肝炎病毒和其他病原体的感染的抗原，使得疫苗的施用可以同时针对多于一种的病原体免疫受试者。 本发明特别涉及包含上述抗原的完全液体稳定的组合疫苗及其制备方法。

公开(公告)号：US20130253029A1

公开(公告)日：2013-09-26

申请号：US13876757

申请日：2011-09-27

申请人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

发明人： Rajesh Jain ,  Sanjay Trehan ,  Jagattaran Das ,  Nishan Singh ,  Sudhir Kumar Sharma

IPC分类号： C07D209/52 ,  A61K45/06 ,  A61K31/403

CPC分类号： C07D209/52 ,  A61K31/403 ,  A61K45/06

摘要： The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).

摘要翻译： 本发明涉及式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂化物。 本发明还涉及合成式I的新化合物，其药学上可接受的衍生物，互变异构形式，异构体，多晶型物，前药，代谢物，盐或溶剂合物的方法。 本发明还提供包含式I化合物的药物组合物和治疗或预防中枢和/或周围神经系统的一种或多种病症的方法，优选通过调节神经和/或精神病学靶标（GPCR和/或非GPCR） 。

公开(公告)号：US20110223249A1

公开(公告)日：2011-09-15

申请号：US12672180

申请日：2008-08-11

申请人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

发明人： Rajesh Jain ,  Sukhjeet Singh ,  Sampath Kumar Devarajan

IPC分类号： A61K31/343 ,  A61K9/00 ,  A61K9/24 ,  A61K9/28 ,  A61P35/00 ,  A61P11/00 ,  A61P25/00 ,  A61P9/00 ,  A61P29/00 ,  A61P31/00

CPC分类号： A61K9/2077 ,  A61K9/2013 ,  A61K9/2846 ,  A61K31/365

摘要： Extended release pharmaceutical compositions comprising mycophenolate sodium as the active agent, wherein the said composition exhibits a characteristic release profile when subjected to in-vitro dissolution study, and wherein said mycophenolate sodium is released in a sustained manner in-vivo for a prolonged duration in such quantities that substantially alleviates or at least reduces the chances of causing any associated gastrointestinal side effect(s) without compromising the bioavailability of the said active agent are provided. The present invention also provides process of preparing dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form. The compositions of the present invention are useful for the management such as prophylaxis, amelioration and/or treatment of immunosuppressant indicated disease(s)/disorder(s) especially for the treatment or prevention of organ, tissue or cellular allograft or xenograft rejection, e.g. after transplant, or the management of immune-mediated diseases (autoimmune diseases).

摘要翻译： 包含霉酚酸钠作为活性剂的延长释放药物组合物，其中当进行体外溶出研究时，所述组合物表现出特征性释放曲线，并且其中所述霉酚酸钠以持续的方式在体内以这种方式长时间释放 提供了大大减轻或至少降低引起任何相关胃肠道副作用而不损害所述活性剂的生物利用度的机会的量。 本发明还提供了使用这种剂型的剂型组合物和预防和/或治疗方法的制备方法。 本发明的组合物可用于治疗，例如预防，改善和/或治疗指示的疾病/病症，特别是用于治疗或预防器官，组织或细胞同种异体移植物或异种移植物排斥反应的免疫抑制剂，例如， 移植后，或免疫介导的疾病（自身免疫性疾病）的管理。

公开(公告)号：US20100234288A1

公开(公告)日：2010-09-16

申请号：US12294482

申请日：2007-03-19

申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sampath Kumar Devarajan

IPC分类号： A61K38/16 ,  A61K31/7088 ,  A61K31/437 ,  A61K31/5513 ,  A61K31/5415 ,  A61K31/5517 ,  A61K31/554 ,  A61K31/496 ,  A61P25/18

CPC分类号： A61K9/2853

摘要： Sustained release pharmaceutical composition comprising at least one poorly soluble active agent(s), at least one solubilizer, a release rate controlling polymer system consisting of an acid-soluble polymer and a pH-dependent polymer, and optionally other pharmaceutically acceptable excipients. The present invention also describes a process for preparation of such compositions and method of using such compositions. The sustained release compositions are useful in providing therapeutically effective levels of active agent(s) for extended periods of time.

摘要翻译： 包含至少一种不易溶解的活性剂，至少一种增溶剂，由酸溶性聚合物和pH依赖聚合物组成的释放速率控制聚合物体系以及任选其它药学上可接受的赋形剂的缓释药物组合物。 本发明还描述了这种组合物的制备方法和使用这种组合物的方法。 持续释放组合物可用于在长时间内提供治疗有效水平的活性剂。

公开(公告)号：US20100204333A1

公开(公告)日：2010-08-12

申请号：US11988860

申请日：2006-07-19

申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

IPC分类号： A61K31/18 ,  A61P25/00 ,  A61P25/06

CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5084 ,  A61K31/18 ,  A61K31/192 ,  A61K31/415

摘要： Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (Cmax) after at least about 1 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form.

摘要翻译： 提供了包含至少一种环加氧酶酶抑制剂或其药学上可接受的盐，酯，前药，溶剂化物或其衍生物作为活性剂的药物改性释放剂型，以及用于控制环加氧酶抑制剂释放的药学上可接受的载体。 根据本文所述的溶解方法（I）测试时，剂型优选在12小时后提供不超过约60％的环氧合酶抑制剂的释放量，并且不少于约75％的环氧合酶抑制剂。 使用2.0％十二烷基硫酸钠作为溶解介质的蒸馏水或根据本文所述的溶解方法（II），使用pH 7.0的磷酸盐缓冲液，含有2.0％十二烷基硫酸钠作为溶解介质，或根据溶解方法（III） 本文使用0.001N盐酸与1.0％十二烷基硫酸钠作为溶解介质。 此外，当在一组健康人中测试时，本发明的药物组合物优选在施用剂型至少约1小时后达到平均峰值血浆浓度（C max）。 本发明还提供了制备这种剂型组合物的方法和使用这种剂型的预防和/或治疗方法。

公开(公告)号：US20090258947A1

公开(公告)日：2009-10-15

申请号：US12298054

申请日：2007-04-23

申请人： Rajesh Jain ,  Kour Chand Jindal

发明人： Rajesh Jain ,  Kour Chand Jindal

IPC分类号： A61K31/16 ,  A61P25/00

CPC分类号： A61K31/18 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/485 ,  A61K9/4858

摘要： Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

摘要翻译： 提供了包含尼美舒利或其药学上可接受的盐，酯，溶剂化物或其水合物以及一种或多种药学上可接受的赋形剂的低剂量药物剂型。 本发明还提供了制备这种剂型的方法和使用这种剂型的治疗方法。 低剂量组合物10被设计为表现出这样的生物利用度，其在治疗特别是需要长期治疗方案例如关节炎的NSAID指征的病症中是有效的。 这样的组合物降低了需要长期疗法，易于制备的疾病的治疗成本，并且还导致与尼美舒利治疗相关的剂量相关的副作用的减少。

公开(公告)号：US07195769B2

公开(公告)日：2007-03-27

申请号：US10110134

申请日：2001-04-10

申请人： Amarjit Singh ,  Rajesh Jain

发明人： Amarjit Singh ,  Rajesh Jain

IPC分类号： A61K9/00 ,  A61K9/48 ,  A61K9/52 ,  A61K9/54 ,  A61K9/58

CPC分类号： A61K9/5084 ,  A61K9/146 ,  A61K9/209 ,  A61K31/495 ,  A61K31/455 ,  A61K2300/00

摘要： A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.

摘要翻译： 包含利福平和/或异烟肼的口服抗结核药物的药物组合物，其中利福平和/或其他药物的生物利用度得到增强。 优选地，利福平的生物利用度通过防止其由异烟肼的存在引起的降解来增强。 利福平和/或异烟肼可以以延迟释放和/或延长释放形式存在，使得在pH1和4之间溶解最少量的药物。优选通过用pH敏感剂处理药物来实现利福平和/或异烟肼的延迟释放 聚合物。